MGEN Research and Charts

MGEN - Miragen Therapeutics Inc (Healthcare: Diagnostics & Research)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-07-03)

Last 15.67	Change ⇑ +0.44 (+2.89%)	Volume 396,663
	Open 15.17	High 15.94	Low 14.98

8EMA (Daily) 14.90	40EMA (Daily) 14.46	50EMA (Daily) 14.44	STO (Daily) 36.211	MACD Hist (Daily) 0.021
8EMA (Weekly) 14.653	40EMA (Weekly) 15.90	50EMA (Weekly) 16.24	STO (Weekly) 77.321	MACD Hist (Weekly) 0.665


Company Profile
Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. The company?s main product candidates, MRG-106, MRG-201, MRG-107, and MRG-110. MRG-106 and MRG-201 are currently in Phase 1 clinical trials. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, neuro-inflammation, and revascularization.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.